Interestingly, mutations in NRF2, KEAP1, and CUL3 were mutually exclusive, suggesting that they all follow the same mechanism to provide a growth advantage to cancer cells, i.e., hyperactivation of NRF2 [66,67]. The gene discussed is NFE2L2; the disease is cancer.